For the roughly 400,000 people diagnosed globally each year with kidney cancer, the post-surgical window represents both the greatest opportunity and the most anxious period — when microscopic residual disease can seed a relapse. A large Phase 3 trial now suggests that combining two mechanistically distinct agents after resection meaningfully extends the time patients stay disease-free, potentially redefining the adjuvant standard of care for clear-cell renal-cell carcinoma.
The KEYNOTE-B61 trial enrolled 1,841 participants at elevated recurrence risk following kidney removal, randomly assigning them in equal numbers to pembrolizumab — an established PD-1 checkpoint inhibitor — plus either the HIF-2α inhibitor belzutifan (120 mg daily) or placebo, each administered for up to one year. At a median follow-up of 28.4 months, the combination arm achieved a hazard ratio of 0.72 for disease recurrence or death (95% CI 0.59–0.87, p<0.001), translating to 24-month disease-free survival rates of 80.7% versus 73.7%. Overall survival data remain immature at this interim cut, with only 29% of final-analysis events observed.
The mechanistic logic here is compelling. Pembrolizumab releases immune brakes on T-cell surveillance, while belzutifan targets HIF-2α — a transcription factor that drives tumor angiogenesis and metabolic adaptation under low oxygen, a hallmark of clear-cell RCC biology. These pathways are largely non-overlapping, making rational combination sensible rather than speculative. Belzutifan already carries FDA approval for advanced VHL-mutation-driven RCC and metastatic disease, so its adjuvant deployment extends a validated mechanism into an earlier, higher-stakes setting.
Key limitations warrant caution: overall survival benefit remains unproven at this juncture, the follow-up window of under three years is modest for a cancer capable of relapsing a decade post-surgery, and the safety profile of dual therapy — particularly anemia and hypoxia-related effects known with belzutifan — will require close longitudinal scrutiny. Nevertheless, a 7-percentage-point absolute improvement in two-year disease-free survival in a phase 3 double-blind trial is a clinically meaningful signal, not an incremental one. This finding is potentially practice-changing pending survival maturation.